Therefore, KHYG1 NK cells could be considered as an NK cell pool with low CD38 expression that can survive from Daratumumab-mediated NK cell decrease while still capable of mounting a cytotoxic response against MM target cells. This evidence concerns the gene CD38 and Miyoshi myopathy.